# VE303 for Prevention of Recurrent Clostridioides Difficile Infection

> **NCT06237452** · PHASE3 · RECRUITING · sponsor: **Vedanta Biosciences, Inc.** · enrollment: 852 (estimated)

## Conditions studied

- Clostridium Difficile
- Clostridium Difficile Infections
- Clostridium Difficile Infection Recurrence
- Clostridioides Difficile Infection
- Clostridioides Difficile Infection Recurrence
- CDI
- C. Diff Infection
- Recurrent Clostridium Difficile Infection
- C.Difficile Diarrhea
- Diarrhea Infectious

## Interventions

- **BIOLOGICAL:** VE303
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06237452
- **Lead sponsor:** Vedanta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2027-06
- **Final completion:** 2027-10
- **Target enrollment:** 852 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06237452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06237452, "VE303 for Prevention of Recurrent Clostridioides Difficile Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06237452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*